We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 28, 2020

Treatments After Progression on First-Line FOLFOXIRI and Bevacizumab in Metastatic Colorectal Cancer

British Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Cancer
Treatments After Progression to First-Line FOLFOXIRI and Bevacizumab in Metastatic Colorectal Cancer: A Pooled Analysis of TRIBE and TRIBE2 Studies by GONO
Br. J. Cancer 2020 Oct 07;[EPub Ahead of Print], D Rossini, S Lonardi, C Antoniotti, D Santini, G Tomasello, P Ermacora, MM Germani, F Bergamo, V Ricci, S Caponnetto, R Moretto, A Zaniboni, F Pietrantonio, A Buonadonna, G Ritorto, G Masi, TP Latiano, S Rapisardi, A Falcone, C Cremolini

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading